Pfizer buy Array BioPharma for $11.4 billion

Pfizer has said it will acquire Colorado-based cancer specialist Array BioPharma for $11.4 billion.

Pfizer has announced that it has entered into a definitive merger agreement under which it will acquire Array – a commercial stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted small molecule medicines for cancer and other diseases with high unmet need.

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.